Alzamend Neuro, Inc.
NASDAQ:ALZN
1.65 (USD) • At close November 4, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Alzamend Neuro, Inc. |
Symbool | ALZN |
Munteenheid | USD |
Prijs | 1.65 |
Beurswaarde | 7,384,361 |
Dividendpercentage | 0% |
52-weken bereik | 1.4 - 20 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Stephan Jackman |
Website | https://www.alzamend.com |
An error occurred while fetching data.
Over Alzamend Neuro, Inc.
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder,
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)